Regencell Bioscience's 15min chart shows MACD Death Cross, Bearish Marubozu.

Regencell Bioscience's 15-minute chart has triggered a MACD Death Cross and a Bearish Marubozu pattern at 10/03/2025 14:00. This indicates that the stock price may experience further decline, with sellers dominating the market, and bearish momentum likely to persist.

Regencell Bioscience Holdings Limited (NASDAQ: RGC), a Hong Kong-based biopharmaceutical company specializing in Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD), has seen its stock price exhibit significant volatility and bearish indicators. On October 3, 2025, at 14:00, the company's 15-minute chart triggered a MACD Death Cross and a Bearish Marubozu pattern, signaling potential further decline in stock price. These technical indicators suggest that sellers are dominating the market, and bearish momentum is likely to persist Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

Regencell Bioscience's inclusion in the S&P Global BMI Index on September 21, 2025, was a notable milestone, boosting its visibility among institutional and passive investors. However, the company continues to face fundamental challenges, including zero revenue, ongoing losses, and uncertain regulatory pathways for its treatments. Despite positive results from its second efficacy trial, with a mean symptom improvement of 37% for ADHD and ASD, no FDA-approved products have been announced yet, and the treatments remain investigational Regencell Bioscience Holdings Limited (RGC) Added to S&P Global BMI Index Amid Positive ADHD/ASD Trial Results^[1].

The stock's extreme volatility in mid-2025, reaching a peak of approximately 14,899% year-to-date gain by June, was driven by speculative trading, a stock split, and excitement over trial results. Following this peak, shares experienced sharp intra-day swings and a pullback. Technical indicators in September suggested a potential upward trend, supported by positive momentum and movement above its 50-day moving average. However, the recent bearish signals indicate a shift in market sentiment, with sellers likely to continue exerting pressure on the stock price.

Investors should remain cautious, as the company's financial health and regulatory uncertainties pose significant risks. While Regencell Bioscience holds promise in the development of TCM treatments, the current market conditions and technical indicators suggest a cautious approach.